Evidence map›Paper›PMID 41910915›Full record

ArticleEJNMMI radiopharmacy and chemistry2026

Preliminary biological evaluation of a [

Dengke Li, Yu Zhang, Chao Mu, Xuecen Cao, Mumei Chen, Xiao Li, Wenxin Chen, Zheng Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dengke Li *Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, China.
Yu Zhang *Department of Nuclear Medicine, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, 350001, China.
Chao MuShanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, China.
Xuecen CaoShanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, China.
Mumei ChenShanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, China.
Xiao LiShanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, China.
Wenxin ChenDepartment of Nuclear Medicine, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, 350001, China. wenxinchzt@aliyun.com.
Zheng LiShanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, China. lizheng04@sinap.ac.cn.ORCID https://orcid.org/0000-0002-5331-2417

Funding

Joint Funds for the Innovation of Science and Technology, Fujian Province 2023Y9602Key Project of Frontier Technology, Shanghai Institute of Applied Physics, Chinese Academy of Sciences SINAP-QYJS-202401Natural Science Foundation Youth Project of Fujian Province 2023J0111191
6 · The paper itself

Abstract

backgroundDespite the clinical implementation of Nectin-4-targeted antibody-drug conjugates (ADCs) and radioligand therapies (RLTs), their therapeutic window is often restricted by systemic toxicities and the emergence of drug resistance. To circumvent these limitations, we developed [

resultsThe synthesis of [

conclusionsThese findings characterize [

Indexed as

Nectin-4RadiopharmaceuticalsSW780Therapeutic efficacy

Identifiers

PMID41910915
PMCPMC13035971

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.